Table 1.

Studies supporting survival differences in women with HR+/HER2-breast cancer.

Study	Patient Number	Population Description	Median Follow-Up	Survival Measure	Risk
O’Brien et al. [5]	246 Black, 379 White	Carolina Breast Cancer Study	9.0 years	BCSS a	HR b 1.9 (95% CI 1.3–2.8)
Sparano et al. [13]	176 Black, 2803 White	Randomized phase III trial	95 months	BCSS	HR 1.65, 95% CI 1.11–2.46
Ma et al. [4]	244 Black, 405 White	Women’s CARE study	10 years	BCSS	HR 1.52, 95% CI 1.01–2.28)
Warner et al. [6]	365 Black, 6763 White	NCCN network centers	6.2 years	BCSS	HR 1.76, 95% CI 1.09–2.85
Tao et al. [14]	4813 Black, 59,341 White	California Cancer Registry	3.5 years	BCSS	HR 1.27, 95% CI 1.12–1.43
Vidal et al. [15]	521 Black, 1326 White	Memphis, TN	29.9 months	All-cause	HR 1.87, 95% CI 1.33–2.62
Collin et al. [9]	2074 Black, 3511 White	Metropolitan Atlanta	3.5 years	BCSS	HR 2.43, 95% CI 1.99–2.97
Zhao et al. [16]	613 Black, 1062 White	Chicago Multiethnic Epidemiologic Breast Cancer Cohort	6.9 years	BCSS	HR 2.37, 95% CI 1.60–3.50)
Lorona et al. [11]	20,152 Black, 148,745 White	SEER database	34 months	BCSS	HR varies by stage and age group
Zhou et al. [17]	2763 Black, 38,951 White	SEER−Medicare Linked Database	7 years	Breast cancer recurrence	Subdistribution HR 1.27, 95% CI 1.15–1.40
Albain et al. [8]	693 Black, 8189 White	TAILORx Trial	90 months	DFS c	HR 1.28, 95% CI 1.05–1.57
Sadigh et al. [12]	693 Black, 8189 White	TAILORx Trial	96 months	RFS d	HR 1.39, 95% CI 1.05–1.84
Du [10]	27,279 Black, 211,344 White	SEER database		BCSS	HR 1.21, 95% CI 1.06–1.37

^a BCSS = breast cancer-specific survival; ^b HR = hazard ratio; ^c DFS = disease-free survival; ^d RFS = recurrence-free survival.